Venus Medtech (Hangzhou), Inc. Class H
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.59 HKD
−774.47 M HKD
510.49 M HKD
394.36 M
About Venus Medtech (Hangzhou), Inc. Class H
Sector
Industry
CEO
Hou-Sen Lim
Website
Headquarters
Wanchai
Founded
2009
IPO date
Dec 10, 2019
IPO offer price
4.22 USD
Identifiers
2
ISINCNE100003PJ8
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. It engages in the research and development of cardiac intervention system for heart diseases. The company offers pre-implanted invasive heart valve systems such as transcatheter artery and pulmonary artery valve systems, and delivery catheter systems. The company was founded on July 3, 2009 and is headquartered in Hangzhou, China.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2500 is 2.47 HKD — it has increased by 4.22% in the past 24 hours. Watch Venus Medtech (Hangzhou), Inc. Class H stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange Venus Medtech (Hangzhou), Inc. Class H stocks are traded under the ticker 2500.
2500 stock has risen by 7.86% compared to the previous week, the month change is a 7.86% rise, over the last year Venus Medtech (Hangzhou), Inc. Class H has showed a −56.67% decrease.
2500 reached its all-time high on Oct 12, 2020 with the price of 97.00 HKD, and its all-time low was 1.59 HKD and was reached on Mar 18, 2025. View more price dynamics on 2500 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2500 stock is 9.62% volatile and has beta coefficient of 0.53. Track Venus Medtech (Hangzhou), Inc. Class H stock price on the chart and check out the list of the most volatile stocks — is Venus Medtech (Hangzhou), Inc. Class H there?
Today Venus Medtech (Hangzhou), Inc. Class H has the market capitalization of 1.08 B, it has decreased by −4.58% over the last week.
Yes, you can track Venus Medtech (Hangzhou), Inc. Class H financials in yearly and quarterly reports right on TradingView.
Venus Medtech (Hangzhou), Inc. Class H is going to release the next earnings report on Mar 27, 2026. Keep track of upcoming events with our Earnings Calendar.
2500 earnings for the last half-year are −0.34 HKD per share, whereas the estimation was −0.38 HKD, resulting in a 11.43% surprise. The estimated earnings for the next half-year are −0.33 HKD per share. See more details about Venus Medtech (Hangzhou), Inc. Class H earnings.
Venus Medtech (Hangzhou), Inc. Class H revenue for the last half-year amounts to 205.06 M HKD, despite the estimated figure of 315.65 M HKD. In the next half-year revenue is expected to reach 483.27 M HKD.
2500 net income for the last half-year is −144.77 M HKD, while the previous report showed −550.89 M HKD of net income which accounts for 73.72% change. Track more Venus Medtech (Hangzhou), Inc. Class H financial stats to get the full picture.
No, 2500 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2025, the company has 691 employees. See our rating of the largest employees — is Venus Medtech (Hangzhou), Inc. Class H on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Venus Medtech (Hangzhou), Inc. Class H EBITDA is −244.93 M HKD, and current EBITDA margin is −58.38%. See more stats in Venus Medtech (Hangzhou), Inc. Class H financial statements.
Like other stocks, 2500 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Venus Medtech (Hangzhou), Inc. Class H stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Venus Medtech (Hangzhou), Inc. Class H technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Venus Medtech (Hangzhou), Inc. Class H stock shows the sell signal. See more of Venus Medtech (Hangzhou), Inc. Class H technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.